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The susceptibility of a fourth generation Ouh strain (Paranapanema Valley, São Paulo, Brazil) of  Schistosoma
mansoni to oxamniquine (OXA) and praziquantel (PZQ) was studied. Ten groups of 13 female albino mice each were
infected with 70 cercariae per animal. These mice were medicated orally on the 50th day after infection. Five groups
were given OXA doses of 0, 100, 200, 300 and 400 mg/kg (single doses) and the rest were treated with PZQ doses of
0, 100, 200, and 250 mg/kg/5 days. Each group was sub-divided: 8 animals underwent perfusion after 15 days
treatment, 5 mice followed up for oviposition and their feces were tested every 15 days for miracidia hatching. The
efficacy of the OXA doses of 100 and 200 mg/kg was 66% and 91.4%, respectively and for the 100 mg/kg PZQ dose
it was 90.1%. The follow-up groups with 100 and 200 mg/kg of OXA and PZQ, 100 and 150 mg/kg, showed that they
re-established the oviposition after a period of 60 to 75 days of treatment. The ED50 was 69.6mg/kg  OXA  and 39.4
mg/kg PZQ. The results show the tolerance of the Ouh strain to a dose of 100 mg with both drugs and they appoint
the need for a dose review during the follow up of the oviposition and in monitoring phenomena in the field.
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In Brazil, schistosomiasis mansoni is an important en-
demic disease that affects 11% of the country’s territory
(Silveira 1989). There are about 6.3 million Brazilians suf-
fering from Schistosoma mansoni (Katz & Peixoto 2000).
The studied strain was isolated in the State of São Paulo
where there was a low endemic parasitic focus (Dias et al.
1994).
The chemotherapy used to treat intestinal schistoso-
miasis, today, is based on two drugs, oxamniquine (OXA)
and praziquantel (PZQ). In control programs the parasito-
logical cure with these drugs is generally satisfactory.
Since 1976, OXA has been used on a large scale in control
programs (Silveira 1989). About 10 million Brazilian S.
mansoni carriers have been treated with this drug (Almeida
Machado 1982). It has been reported human strains of  S.
mansoni that have altered their susceptibility (resistance
and/or tolerance) to OXA (Katz et al. 1973, Dias et al.
1978). The tolerance to PZQ has been reported in Senegal
(Stelma et al. 1995) and in Egypt (Ismail et al. 1996), and
even in Brazil, where it is rarely used (Gomes et al. 1993,
Araújo et al. 1996).
These findings support Kinoti’s (1987) supposition
that S. mansoni has a great capacity to develop resis-
tance to therapeutic doses of a determined drug, espe-
cially when the parasitic population is under continuous
pressure from schistosomicides (Coles & Bruce 1990).
It was not possible yet to identify genetic resistance
markers using molecular techniques (Dias Neto et al. 1993,
Araújo et al. 1996). Therefore experimental in vivo chemo-
therapeutic research is indispensable in evaluating the
susceptibility of S. mansoni to schistomocides.
This study deals with in vivo chemotherapy of the
human strain (Ouh) of S. mansoni. Gomes et al. (1993)
showed that the first generation of this strain in mice is
tolerant to OXA and PZQ and with 69.7% and 87.5% of
efficacy respectively.
MATERIALS AND METHODS
S. mansoni strain - The 4th generation Ouh human
strain that was isolated in 1992 from 3 S. mansoni carriers
was used (Gomes et al. 1993). These patients were from
the Ourinhos county (Paranapenema Valley, State of São
Paulo, Brazil) and had never been treated with
schistosomicides. These patients were treated with PZQ
in the Health Center.
Definitive host - Four week old female mice were used.
They were individually infected, through the tail, with 70
cercariae of the 4th generation of the Ouh strain (Olivier
& Stirewalt 1952).
Intermediate host - Three hundred specimens of
Biomphalaria glabrata, melanic and sympatric to the strain
were used. They were individually exposed to 5 miracidia
(Standen 1952).
Experimental groups - Ten groups of 13 mice each
were used in this study. Five groups were treated with
OXA and the rest with PZQ. Each group had two sub-
groups – one with 8 mice that underwent perfusion after
15 days and the other of 5 mice that were maintained in
order to follow up the oviposition of the trematode (fol-
low-up group).
Treatment - The treatments started 50 days after in-
fection using single doses of 100, 200, 300 and 400 mg/kg
of OXA and 100, 150, 200 and 250 mg/kg/5 days of PZQ.
This work was developed between 1993 and 1995, and sup-
ported by Fundação de Amparo à Pesquisa do Estado de São
Paulo.
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Both the drugs were administered in a 1% Cremophor EL
aqueous suspension by oral gavage (Coles et al. 1986).
Pure salt was used in both drugs. Two groups were kept
as untreated control. Therefore, of the 10 groups, 4 groups
were treated with different doses of OXA and 4 groups
with different doses of PZQ.
Follow-up groups - An individual follow up was car-
ried out for a year on 5 animals from each group. This was
done by examining the feces every 15 days for the hatch-
ing of the miracidia (Standen 1952).
Perfusion - Fifteen days after treatment, the animals
were sacrificed and portally perfused (Yolles et al.1947).
After perfusion of the liver and mesentery, the worms were
collected and placed in Petri dishes in a 0.85% saline solu-
tion. They were counted and classified according to their
location, sex and vitality. After perfusion, the liver was
crushed between glass plates to check for worms that
may have been left behind during perfusion (Hill 1956).
Evaluation of susceptibility - The following param-
eters were used for evaluation: (a) the distribution of worms
–  the percentage of worms found in the intrahepatic veins
was calculated in relation to the total number of worms
collected. The worms found in the portal vein were con-
sidered as pertaining to the mesentery; (b) percentage
efficacy (Kemp et al. 1956) – was determined by use of the
following equation: (a - b)/a x 100, where a = average num-
ber of live worms recovered from untreated animals and b
= number of live worms from treated animals; (c) percent-
age oogram change (Pellegrino & Katz 1968) – was calcu-
lated based on the number of mice with altered oogram.
The oogram was considered altered when one of the five
maturity degrees, based on the embryo size and morphol-
ogy, was absent; (d) effective doses (ED) – dose response
curves were generated where response was plotted as %
efficacy on the y-axis against dose (total mg/kg) on the x-
axis. The values of ED were obtained by observing the
dose with intersected the curve dose (Drescher et al. 1993).
RESULTS
A high rate of live worms (males, females, couples)
(54.9%) were found when a dosage of 100 mg/kg OXA
was used (Table I); of the total number of worms, 6.9%
remained in the mesenteric veins after perfusion (Table II)
and in the case of one animal, the oogram was found to be
normal, with eggs in different stages.
When the dose of OXA was 200 mg the percentage of
TABLE I
Total number of worms recovered 15 days after treatment, in the oxamniquine (OXA) and praziquantel (PQZ) groups of mice
infected with 70 cercariae  each of the fourth generation Ouh strain of Schistosoma mansoni
Number of                                        Worms  collected
Dose mice Live Total (live and dead) Mean number of live worms
Drug mg/kg examined N % N Mean Male Female Couples Total
OXA 0 7 245    98.4 249 35.6 7.4±5.2 5.3±3.5 11.1±6.4    34.9
OXA 100 8 95    54.9 173 21.6 2.0±2.9 9.4±5.4   0.3±0.5 12
OXA 200 7 21    23.3   90 12.8 0.0±0.0 3.0±3.8   0.0±0.0   3
OXA 300 8 0     0.0 146 18.2 0.0±0.0 0.0±0.0   0.0±0.0   0
OXA 400 8 1      0.7 149 18.6 0.0±0.0 0.1±0.4   0.0±0.0   0
PZQ 0 X 5 4 134 100.0 134 33.5 5.8±4.6 3.3±3.6 12.3±8.4  33.7
PZQ 100 X 5 7 23   13.3 176 25.1 0.6±1.5 1.9±2.1   0.4±0.8     3.3
PZQ 150 X 5 5 4      2.4 169 33.8 0.2±0.4 0.2±0.4   0.2±0.4     0.8
PZQ 200 X 5 7 4      2.5 158 22.6 0.0±0.0 0.6±1.5   0.0±0.0     0.6
PZQ 250 X 5 4 5      5.3   94 23.5 0.0±0.0 1.3±1.5   0.0±0.0     1.3
OXA: single dose, orally; PZQ: 5 consecutive days of treatment, orally
TABLE II
Schistosomocidal activity of oxamniquine (OXA) and praziquantel (PZQ) in mice infected individually with  70 cercariae of the
fourth generation Ouh strain of Schistosoma mansoni
Drug Dose % of  worms   recovered % of dead % of the alteration Efficacy
(mg/kg) Liver Mesentery worms in the liver  of the oograms (%)
OXA 100     93.1    6.9     77.0     87.5     66.0
OXA 200     98.9    1.1     75.6 100     91.4
OXA 300 100 0 100 100 100
OXA 400 100 0     99.3 100     99.7
PZQ 100     96.6    3.4     86.9     83.3     90.1
PZQ 150 100 0     97.6 100     97.6
PZQ 200 100 0     97.5 100     98.2
PZQ 250     98.9    1.1     94.7 100     96.1
OXA: single dose, orally; PZQ: 5 consecutive days of treatment, orally
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female worms was relatively high (23.3%) (Table I) and
according to the oogram there was an interruption of the
ovoposition in all the mice (Table II). The percentage of
efficacy in the case of 100 mg/kg and 200 mg/kg doses
was 66% and 91.4% respectively (Table II). Those groups
of animals that were treated with 300 mg/kg and 400 mg/
kg doses reported practically a total absence of live worms,
which resulted in a 100% efficacy (Table II). The percent-
ages of worms recovered were calculated according to
live and dead worms combined. The number of dead worms
in the liver was recovered by perfusion and crushing.
In the case of PZQ, when the dosage was 100 mg/kg/
5days, the number of live worms (females, males and
couples) was relatively high (13.3%) (Table I). When the
dosage was 150 mg, 2.4% of live worms of all kinds were
found but when the dosage was higher, it is important to
note that only live female worms were found (Table I).
Mice treated with 100 mg/kg showed the least efficacy
(90.1%) and for the rest of the groups the efficacy was
higher than 96.1% (Table II).
The follow up in the case of the 2 control groups,
OXA (5 mice) and PZQ (5 mice), was possible for just 105
days as most of them died between the 90th and 105th
day. The test showed the presence of fully developed
trematode eggs.
Two groups of mice medicated with single doses of
100 mg/kg and 200 mg/kg of OXA regained oviposition.
This took place 75 days after being medicated with 100
mg/kg OXA in one animal and the condition was main-
tained until the experiment terminated (360 days, follow-
up). With a dosage of 200 mg/kg, the oviposition was
recovery in two mice after 60 days and continued till the
end. In the case of the remaining doses – 300 mg/kg and
400 mg/kg, the oviposition was not re-established.
In those groups treated with PZQ, the process of egg
elimination through the feces was re-established in 2 mice,
60 days after receiving 100 mg/kg/5days and in 1 animal
that was medicated with 150 mg/kg/5days and this condi-
tion was maintained for 360 days. The elimination of eggs
through the feces did not take place in the animals medi-
cated with 200 mg/kg/5days and 250 mg/kg/5days.
The effective doses (ED50) were: a single dose of 69.6
mg/kg OXA and 39.4 mg/kg of PZQ for 5 consecutive days.
DISCUSSION
Our results show that the susceptibility of the Ouh
strain to OXA and  PZQ has changed when compared to
results obtained for Brazilian strains by other Brazilian
authors (Katz et al. 1973, Dias et al. 1978, Araújo et al.
1996). Gomes et al. (1993) showed that efficacy of OXA
and PZQ on the F1 generation of the parasite was 69.7%
and 87.5%, respectively. The doses used on mice were
only 100 mg/kg for both drugs.
We studied the 4th generation of this same strain and
the OXA and PZQ efficacy obtained was 66% and 90.1%,
respectively (Table II). In the case of the Brazilian strains
the efficacy is generally more than 95% and other param-
eters show a high susceptibility to these schistosomicides
(Dias et al. 1982, 1988, Drescher et al. 1993). Recently,
Araújo et al. (1996) studied ten isolates of S. mansoni
derived from patients in an endemic area in Bahia, Brazil.
They were treated with OXA and later with PZQ and were
not parasitologically cured. The in vivo therapeutic re-
sponse of these isolated types was significantly different
among them, but not enough to be able to characterize
any of them as being resistant. The authors reported that
a single dose of 100 mg/kg OXA showed an efficacy be-
tween 48% to 92.4% and a single dose of 400 mg/kg PZQ
an efficacy between 30.4% to 90.2%.
It is important to stress the fact that we used a thera-
peutic scheme that consisted of curative doses adminis-
tered when the worms were at the adult stage (50 days
old). This condition is generally found in regions where
the endemicity of schistosomiasis mansoni is low. Situa-
tions in which mice with younger worms (35 to 37 days
after infection) were treated with sub-curative doses of
schistosomicides (Fallon et al. 1997) did not show to rep-
resent the reality observed in the case of human in the
field.
It was observed that perfused animals had adult live
worms (males, females and couples) (Table I) during thera-
peutic treatment with OXA and PZQ, especially when the
dosage was 100 mg/kg/single dose and 100 mg/kg/5
days.The male is more susceptible to the 2 drugs than the
female, which explains the survival of a larger number of
females (Goldberg et al. 1980, Popiel & Erasmus 1982).
Recovery of the oviposition of the worms that sur-
vived after treatment (60 to 75 days) was faster than that
shown by Rogers and Bueding (1971), which was a period
of 6 to 12 months in the case of the S. mansoni strain in
which resistance to hycanthone was induced. The period
was more than 100 days for adult trematode worms in
mice treated with sub-curative doses of PZQ (Shaw &
Erasmus 1987). This distinct behavior of our strain could
be related to the care taken in using a recently isolated
field helminth, thus maintaining the original characteris-
tics that are usually lost when strains are kept in the labo-
ratory for a long time.
The ED of OXA that killed 50% of the worms was a
single dose of 69.6 mg/kg given orally. This value was 34
mg/kg greater than that found by Drescher et al. (1993) for
the BH strain (Belo Horizonte, Brazil) but was closer to
the value of 62 mg/kg obtained for the K strain (Kenya).
Both strains are considered sensitive to OXA. In relation
to the resistant strains to this drug, the values obtained
by the above authors were 320 mg/kg for MAP (Belo
Horizonte, Brazil) and 512 mg/kg for MPR-1 (Porto Rico).
Araújo et al. (1996) worked on 10 isolates obtained from
patients who were treated and not cured by OXA and
PZQ, found that in mice the ED50 varied between 30 mg/
kg to 100 mg/kg with OXA administered in single dose.
In the case of PZQ, using 100 mg/kg/5 days we ob-
tained an ED50 of  39.4 mg/kg. Drescher et al. (1993)
worked with the strains BH, K, MAP and MPR-1, previ-
ously mentioned and obtained an ED50 of 42, 36, 13 e 46
mg/kg/5 days, respectively, by oral route. Araújo et al.
(1996) worked with single doses of PZQ obtained in  ED50
that varied between 92 mg/kg and 640 mg/kg. Bennett et
al. (1997) worked with isolates from infected Egyptian vil-
lagers, that in the field tolerate high doses of PZQ and
could not be cured after 3 doses, obtained ED50 values
ranged between 123 to 680 mg/kg in a single dose.
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When studying the susceptibility of S. mansoni, the
following factors have to be observed: identifying the
drug pressure, using curative dosage when the worms
are adults, follow up of the oviposition, changes in the
oogram and parameters like percentage of efficacy and
effective doses. Taking into consideration the above
points, the Ouh strain showed a change in susceptibility
to OXA and PZQ. This degree of susceptibility shown by
the mice to the two drugs and the recovery of eggs
strengthens the preoccupation about an increase of in-
sensitivity in the field (Cioli 2000).
Faced with these problems, the doses for both drugs
have to be reviewed, the Ouh sub-strains have to be iso-
lated using drug pressure and new schistomocides have
to be tested (Penido et al. 1994). It is important to study
the possible alterations at a genomic level of this strain to
PZQ in comparison to another that is sensitive or resis-
tant to OXA/hycanthone (Brindley et al. 1991, Pica-
Mattoccia et al. 1993, Cioli 2000).
As a result of our findings and of those that showed
that the strains of S. mansoni were tolerant and/or resis-
tant to PZQ (Gomes et al. 1993, Stelma et al. 1995, Ismail et
al. 1996, Fallon et al. 1997), there should be rigorous moni-
toring of these phenomenona (Cioli 2000). It is clear that
only two drugs, OXA and PZQ are available for use in
mansonic schistosomiasis control programs. We should
remember that chemotherapy is just one of the means used
in reducing infection and morbidity. Long term measures
like education, sanitation, permanent primary health care
and safe water supply should also be provided.
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